From the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiol Rev. 2024;32(4):378-383. doi: 10.1097/CRD.0000000000000530. Epub 2023 Mar 22.
Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to improve contractility via indirect mechanisms but are limited in terms of safety and effectiveness. Omecamtiv mecarbil is a novel agent in a new class of drugs known as cardiac myosin activators; their unique mechanism of action involves directly activating the enzymatic pathway in the cardiac myocyte as a way to improve ventricular contraction. Preclinical and clinical trials have found that omecamtiv mecarbil improves cardiac contractility without increasing the risk of any of the harmful effects that are associated with the currently available inotropic agents. Omecamtiv mecarbil is a worthwhile advance and patients with systolic heart failure would benefit from pharmacological use of this drug.
收缩性心力衰竭是一种复杂的临床综合征，其特征是心肌收缩力下降和器官灌注减少。目前的药理学正性肌力药物试图通过间接机制改善收缩力，但在安全性和有效性方面存在局限性。Omecamtiv mecarbil 是一种新型药物，属于一种新型药物类别，称为心肌肌球蛋白激活剂；它们的独特作用机制涉及直接激活心肌细胞中的酶促途径，以改善心室收缩。临床前和临床试验发现，Omecamtiv mecarbil 可改善心肌收缩力，而不会增加与现有正性肌力药物相关的任何有害作用的风险。Omecamtiv mecarbil 是一个有价值的进展，患有收缩性心力衰竭的患者将受益于这种药物的药理学使用。
